跳转至内容
Merck
CN
  • Persistent reduction of hippocampal glutamine synthetase expression after status epilepticus in immature rats.

Persistent reduction of hippocampal glutamine synthetase expression after status epilepticus in immature rats.

The European journal of neuroscience (2014-10-29)
W Saskia van der Hel, Ellen V S Hessel, Ineke W M Bos, Sandra D Mulder, Suzanne A M W Verlinde, Pieter van Eijsden, Pierre N E de Graan
摘要

Mesiotemporal sclerosis (MTS), the most frequent form of drug-resistant temporal lobe epilepsy, often develops after an initial precipitating injury affecting the immature brain. To analyse early processes in epileptogenesis we used the juvenile pilocarpine model to study status epilepticus (SE)-induced changes in expression of key components in the glutamate-glutamine cycle, known to be affected in MTS patients. SE was induced by Li(+) /pilocarpine injection in 21-day-old rats. At 2-19 weeks after SE hippocampal protein expression was analysed by immunohistochemistry and neuron damage by FluoroJade staining. Spontaneous seizures occurred in at least 44% of animals 15-18 weeks after SE. As expected in this model, we did not observe loss of principal hippocampal neurons. Neuron damage was most pronounced in the hilus, where we also detected progressive loss of parvalbumin-positive GABAergic interneurons. Hilar neuron loss (or end-folium sclerosis), a common feature in patients with MTS, was accompanied by a progressively decreased glutamine synthetase (GS)-immunoreactivity from 2 (-15%) to 19 weeks (-33.5%) after SE. Immunoreactivity for excitatory amino-acid transporters, vesicular glutamate transporter 1 and glial fibrillary acidic protein was unaffected. Our data show that SE elicited in 21-day-old rats induces a progressive reduction in hilar GS expression without affecting other key components of the glutamate-glutamine cycle. Reduced expression of glial enzyme GS was first detected 2 weeks after SE, and thus clearly before spontaneous recurrent seizures occurred. These results support the hypothesis that reduced GS expression is an early event in the development of hippocampal sclerosis in MTS patients and emphasize the importance of astrocytes in early epileptogenesis.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氯化锂, ACS reagent, ≥99%
Sigma-Aldrich
高锰酸钾, ACS reagent, ≥99.0%
Sigma-Aldrich
邻二甲苯, puriss. p.a., ≥99.0% (GC)
Sigma-Aldrich
氯化锂, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Sigma-Aldrich
氯化锂, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
氯化锂, ReagentPlus®, 99%
Sigma-Aldrich
氯化锂 溶液, 8 M, Molecular Biology, ≥99%
Sigma-Aldrich
邻二甲苯, reagent grade, ≥98.0%
Sigma-Aldrich
氯化锂, Molecular Biology, ≥99%
Sigma-Aldrich
高锰酸钾, ACS reagent, ≥99.0%, low in mercury
Sigma-Aldrich
氯化锂, powder, ≥99.98% trace metals basis
Supelco
电解液 溶液, nonaqueous, 2 M LiCl in ethanol
Supelco
邻二甲苯, suitable for HPLC, 98%
Sigma-Aldrich
高锰酸钾, 97%
Sigma-Aldrich
邻二甲苯, anhydrous, 97%
Supelco
氯化锂 溶液, 1 M in ethanol
Supelco
电解液, nonaqueous, LiCl in ethanol (saturated)
Supelco
邻二甲苯, analytical standard
Sigma-Aldrich
氯化锂, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
氯化锂, BioUltra, Molecular Biology, anhydrous, ≥99.0% (AT)
Sigma-Aldrich
氯化锂, puriss. p.a., anhydrous, ≥99.0% (AT)
Sigma-Aldrich
氯化锂, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Supelco
邻二甲苯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
氯化锂, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Sigma-Aldrich
高锰酸钾, puriss., meets analytical specification of Ph. Eur., BP, USP, 99-100.5%
Sigma-Aldrich
氯化锂-7Li, 99 atom % 7Li, 99% (CP)
氯化锂 溶液, 2 M in ethanol
Sigma-Aldrich
p-Xylene-bis(N-pyridinium bromide), ≥95% (TLC)
Sigma-Aldrich
高锰酸钾, LR, ≥99%
Sigma-Aldrich
氯化锂, Vetec, reagent grade